Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wild-type p53 protein activity. Here, we explored the predictive and prognostic valu...

Full description

Bibliographic Details
Main Authors: Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Ostenstad, Steinar Lundgren, Terje Risberg, Ingvil Mjaaland, Gudbrand Skjønsberg, Turid Aas, Ellen Schlichting, Hans E Fjösne, Arne Nysted, Johan Richard Lillehaug, Per Eystein Lønning
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-04-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3083424?pdf=render

Internet

http://europepmc.org/articles/PMC3083424?pdf=render

Similar Items